Clinical Trials Directory

Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes. Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : lenalidomide

Phase: Phase 1


Ages Eligible For Study:

1 Year - 21 Years

External Links

Explore related trials

Contact information

Primary Contact:

LPCH New Patient Coordinator 6507251072

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: